Human Cytolytic Fusion Proteins: Modified Versions of Human Granzyme B and Angiogenin Have the Potential to Replace Bacterial Toxins in Targeted Therapies against CD64+ Diseases-Reference-Cited by-同舟云学术

Human Cytolytic Fusion Proteins: Modified Versions of Human Granzyme B and Angiogenin Have the Potential to Replace Bacterial Toxins in Targeted Therapies against CD64+ Diseases

Published:2014-02-19 Issue:1 Volume:3 Page:92-115
ISSN:2073-4468
Container-title:Antibodies
language:en
Short-container-title:Antibodies

Author:

Berges Nina,Hehmann-Titt Grit,Hristodorov Dmitrij,Melmer Georg,Thepen Theo,Barth Stefan

Publisher

MDPI AG

Subject

Drug Discovery,Immunology,Immunology and Allergy

Link

http://www.mdpi.com/2073-4468/3/1/92/pdf

Reference143 articles.

1. Maturing antibody–drug conjugate pipeline hits 30

2. In vivostudies of whole ricin monoclonal antibody immunoconjugates for the treatment of murine tumours

3. Antibody-Based Immunotoxins for the Treatment of Cancer

4. FDA Grants Full Approval to ONTAK® (denileukin diftitox) For Use in Patients with Cutaneous T-Cell Lymphoma (CTCL)http://www.eisai.com/news/news200852.html

5. Therapeutic targets and recent advances in protein immunotoxins

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD64: An Attractive Immunotherapeutic Target for M1-type Macrophage Mediated Chronic Inflammatory Diseases;Biomedicines;2017-09-12

2. Recombinant Immunotoxins for Chronic Inflammatory Disease;Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins;2017

3. The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia;International Journal of Cancer;2015-06-12

4. Engineered Versions of Granzyme B and Angiogenin Overcome Intrinsic Resistance to Apoptosis Mediated by Human Cytolytic Fusion Proteins;Resistance to Targeted Anti-Cancer Therapeutics;2015